Gómez GL, González SY, Cáceres PMA, Nápoles CB, Téllez GR, Fabelo BO

Language: Spanish
References: 21
Page:
PDF size: 54.49 Kb.

ABSTRACT

Introduction: cervical uterine cancer incidence has increased lately and currently it is the first leading cause of death in women in some countries of Latin America.
Objective: to characterize patients with altered organic cytologies in the Tula Aguilera Unviversity Polyclinic.
Methods: we conducted a cross-sectional study in patients with altered functional cytology in the Policlinico Universitario "Tula Aguilera" of Camagüey municipality from August 2010 to January 2011. The study group consisted of 180 patients and the sample consisted of 115 women who met the inclusion criteria and were treated at the provincial consultation Cervical Pathology Maternity Hospital "Ana Betancourt de Mora". The information was stored in a database created using the Excel program of Office XP.
Results: the age group 35 to 39 ( 27.8 %) prevailed. Most of the patients had CIN II (54.8 %), and 83.5 % of patients had started their first sexual intercourse at the age of 19 or younger. 59.1 % of patients had one to three sexual partners. Vaginal thrush infection was more frequent.
Conclusions: It was prevalent in the age group between 35 and 39. Consequently, there were prevalent CIN II, the onset of sexual intercourse before age 20, and up to three sexual partners in the last year.

REFERENCES

1. MINSAP Programa Nacional de Diagnóstico Precoz del Cáncer Cérvicouterino. La Habana: Ed. Ciencias Médicas; 2007.

2. Valdés Álvarez O, Vasallo N, Peña Cedeño P. Estadio I del cáncer cervical. Rev Cubana Obstet Ginecol. 2007;23(2):91-6.

3. Torres Lobatón A. Cáncer del cuello uterino. Panorama actual de su epidemiología y factores de riesgo. Ginecol Ostet Mex. 2006;72:466-74.

4. Álvarez Sintes R. Medicina General Integral. En: Colectivo de autores. Principales afecciones en los contextos familiar y social. 2da. ed. La Habana: Editorial Ciencias Médicas; 2008. p. 26-30.

5. Bethesda Brinton LA. Epidemiology of cervical cancer overview. Environmental Epidemiology Branch National Cancer Institute. 2009;2:35-42.

6. Cabeza Cruz, E. Conducta frente a la neoplasia intraepitelial cervical (NIC). Rev Cubana Obstet Ginecol. 2008;3:156-60.

7. Colectivo de autores. Programa Nacional de Diagnóstico Precoz del cáncer cérvicouterino. La Habana: Editorial Ciencias Médicas; 2008. p. 60.

8. LLoret M, Pérez Sofía, Rey A, Lumbrana A, Lara P, Falcón O. Proliferación tumoral en cáncer de cérvix uterino. Relación con los factores clásicos de pronóstico y la supervivencia. Ginecología Clínica y Quirúrgica. 2006;3(2):88-93.

9. Colgon TJ. Pop test results. Responding to Bethesda System reports. Con from o Physicion. Related articles, Books lenkout. 2008;47:1425-30. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11494930

10. Ramírez Gorton JT, Sánchez Valdiviece EA, Soto Pérez C, Muñoz González DE. Histerectomía Radical en cáncer de cérvix Estadio 1B-1. Ginecología y Obstetricia de México. 2009;(66):41-7.

11. Hernández Hernández DM, Hernández Alemán FR, Ornela Bernal LA, Gonzales Lira G, Andado A, Martínez García MC. Cáncer de cuello uterino. Factores sociales, clínicos y reproductivos asociados con lesiones precursoras. Rev Med IMSS. 2009;39(4):325-33.

12. Novoa Vargas A, Padilla Cortés E, Baciles Castaño C. Cáncer cérvico- uterino y embarazo. Experiencia de 5 años en el Hospital de Gineco-Obstetricia No 3. C.M. La Raza del Instituto Mexicano del Seguro Social. Ginecología y Obstetricia de México. 2007;(67):565-70.

13. Pérez LA. HPV genital: Los eslabones al cáncer cervical, tratamiento y prevención. Clin Lab SC. 2009;14(3):183-6.

14. Chirengi ZM, Rusakaniko S, Kirumbi L, Walli EN, Makerta Tlebere P, Makoac L. Situation analysis for cervical cáncer diagnosis and treatment for cervical cancer diatnosis and treatmgnt in East, Central and southn Africa country. Bulletin of the World Health organization. 2006;79(2):127-32.

15. Rodríguez Salva A, Echevarría Aguilera A, Murla Alonso P, Vázquez González C. Factores de riesgo del cáncer cérvix en el Municipio Cerro. Rev Cubana Hig Epidemiol. 2010;37(1):40-6.

16. Sellor JN, Mahory JB, Kaczarowski J, Lytwyn A, Bangura H, Chongs Lurinez A, et al. Prevalence and predictors of human papilomavirus. Infection in women in Ontario, Canada. Survey of HPV in Ontario women (show). Group CMA J. 2009;163(5):503-8.

17. Jobo JK, Ramírez PT. La biología molecular de cáncer cervical. Cáncer Invest. 2008;19(6):621-9. Libros, linkout. Disponible en: http://redalyc.uaemex.mx/redalyc/pdf/1952/195221539004.pdf

18. Milián Vega F, Fernández Alfonzo J, Rodríguez López R, Rodríguez Fernández T. Estudio de algunos factores epidemiológicos en pacientes con citologías anormales. Rev Cubana Obstet Ginecol. 1999;25(3):181-9.

19. Chirengi ZM, Rusakaniko S, Kirumbi L, Ng Walli EN, Makerta Tlebere P, Kaggwas, et al. Situation analysis for cervical cáncer diagnosis and treatment for cervical cancer diagnosis and treatmgnt in East, Central and southn Africa country. Bulletin of the World Health organization. 2008;79(2):127-32.

20. Rengaswamy Sankaranarayanan A, Manichon Rojkumor R. Effective screening programmer for cervical cancer in lowand middle in come developing countries. Bulletin of the world heath organization. 2007;79(10):954-62.

21. Zhang Z. Trichomonas Vaginales and cervical cancer. A prospective study in China department of Epidemiology and Biostadistes, New York, USA. Epidemiology. July 2009;5(4):325-32.